Cardiac biomarkers: a contemporary status report
Alan S Maisel, Vikas Bhalla and Eugene Braunwald
Corrigendum
In the January 2006 issue, the footnote to Table 1 was published as "aN-terminal pro-brain natriuretic peptide has yet to be approved by the FDA for risk-stratification purposes in acute coronary syndromes". This should have appeared as "aN-terminal pro-brain natriuretic peptide has been approved by the FDA for risk-stratification purposes in acute coronary syndromes and recently also for risk-stratification purposes in patients with stable coronary artery disease".
Table 1 The usefulness of inflammatory biomarkers in diagnosis and risk stratification in acute coronary syndromes.
Full tableFigures & Tables indexDownload Power Point slide (246K)
Contact the journal about this article
